WO2012059941A1 - Procédé pour préparation de malate de sunitinib et sels correspondants - Google Patents

Procédé pour préparation de malate de sunitinib et sels correspondants Download PDF

Info

Publication number
WO2012059941A1
WO2012059941A1 PCT/IN2011/000748 IN2011000748W WO2012059941A1 WO 2012059941 A1 WO2012059941 A1 WO 2012059941A1 IN 2011000748 W IN2011000748 W IN 2011000748W WO 2012059941 A1 WO2012059941 A1 WO 2012059941A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
sunitinib
mixture
preparation
process according
Prior art date
Application number
PCT/IN2011/000748
Other languages
English (en)
Inventor
Shekhar Bhaskar Bhirud
Perminder Singh Johar
Veerender Sharma
Harneet Sandhu
Original Assignee
Ind-Swift Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind-Swift Laboratories Limited filed Critical Ind-Swift Laboratories Limited
Publication of WO2012059941A1 publication Critical patent/WO2012059941A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to an industrially advantageous process for the preparation of sunitinib of formula I,
  • the present invention also provides novel salts of sunitinib and preparation thereof.
  • the present invention further provides an efficient process for the preparation of form I of sunitinib malate.
  • Sunitinib of formula I is a tyrosine kinase inhibitor (T 1) that targets and blocks the signaling pathways of multiple selected receptor tyrosine kinases (RT s) and is chemically known as N-[2- (diethyl amino)ethyl]-5-[(2)-(5-fluoro-l,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- 1 H-pyrrole-3-carboxamide,
  • Formula I It is indicated for the treatment of abnormal cell growth in mammals, particularly in humans and marketed in the United States under the trade name SUTENT® by Pfizer, Inc. SUTENT® is approved by the FDA for the treatment of metastatic malignant gastrointestinal stromal tumor (GIST) and for the treatment of advanced metastatic renal cell carcinoma (MRCC). Sunitinib has been first disclosed in US patent 6,573,293, (referred herein as US '293). US '293 patent discloses synthesis of sunitinib by the following reaction scheme:
  • Sunitinib thus prepared is washed with ethanol, slurried in ethanol, isolated from the slurry by filtration, again washed with ethanol, and dried for 130 hours under vacuum to give an orange solid.
  • Process involves the use of pyrrolidine for the condensation which is very expensive reagent. Further patent is silent about the purity of the sunitinib and also its conversion to sunitinib malate.
  • Process involves protection of carboxylic group prior to condensation reaction which adds an extra step to the process, hence makes the process lengthy.
  • Process involves use of organic base such as triethylamine for condensation.
  • US patent 7,435,832 discloses process for the preparation of sunitinib L-malate by adding malic acid to the solution of sunitinib base in methanol and then methanol is evaporated under reduced pressure resulting in poorly orange solid. A further solvent like acetonitrile is then added to the product to obtain the slurry which is heated and then cooled to obtain the crystal form 1.
  • the patent also discloses two polymorphs of sunitinib malate referred to as form I and form II.
  • condensation reaction of 5-fiuorooxoindole is carried out with 5-formyl indole - 3- carboxylic acid derivative followed by activation of carboxylic group prior to condensation with N,N-diethyl ethylenediamine to form sunitinib.
  • PCT publication WO 2009/150523 discloses a process for the preparation of sunitinib malate without isolating sunitinib by condensation of malate salt of 5-formyl-2,4-lH-pyrrole-3-carboxylic acid-(2-diethylaminoethyl) amide with 5-fluorooxoindole in an organic solvent in presence of an organic amine like pyrrolidine which is then crystallized using water: isopropanol.
  • PCT publication WO 2009/15701 1 discloses a process for the preparation of sunitinib by reacting 5-formyl-2,4-lH-pyrrole-3-carboxylic acid-(2-diethylaminoethyl) amide with 5-fluorooxoindole in a solvent optionally employing a catalyst to give sunitinib, which is then converted to sunitinib malate by refluxing with L-malic acid and a suitable solvent.
  • catalysts such as inorganic bases, quaternary ammonium compound, Lewis acid, organic base, para-toluene sulfonic acid; and the like have been disclosed which can be used to hasten reaction, but examples are found using only basic catalyst such as pyrrolidine, piperidine, sodium bicarbonate, potassium hydroxide, ammonia, sodium methoxide, tert-butyl ammonium hydroxide and potassium fluoride.
  • PCT publication WO 2010/001 167 discloses a process for the preparation of sunitinib by employing different strategy as shown below:
  • Sunitinib prepared by the above process is having purity only 93.87 % as exemplified. Sunitinib base of such low purity is not suitable for the further synthesis of final product i.e. sunitinib malate as purity of the intermediate as well as final compound is important in the field of pharmaceutical chemistry.
  • PCT publication WO 2010/055082 discloses a process for preparation of sunitinib malate by refluxing 5-formyl-2,4-lH-pyrrole-3-carboxylic acid-(2-diethylaminoethyl) amide with 5-fluoro- l ,3-dihydro-indol-2-one in organic solvent in presence of organic base selected from linear amines, cyclic amines (preferably organic base used is pyrrolidine) followed by addition of malic acid to form sunitinib malate.
  • organic base selected from linear amines, cyclic amines (preferably organic base used is pyrrolidine) followed by addition of malic acid to form sunitinib malate.
  • Pyrrolidine is an expensive reagent, highly toxic, causes skin irritation and therefore not suitable for use at industrial scale.
  • Chinese patent application CN 101497607 A discloses a process for preparation of sunitinib by amidation of 2,4-dimethyl-lH-pyrrole-3-carboxylic acid with N ⁇ V-diethyl ethylenediamine using Vilsmeier-Haack reagent followed by condensation with 5-fluoroindolin-2-one in organic solvent in the presence of inorganic or organic base.
  • sunitinib malate There are several polymorphs known in prior art for sunitinib malate, but form I of sunitinib malate has been found to have more thermodynamic stability, higher crystallanity and lower hygroscopicity. Various processes are known for preparation of sunitinib malate form I, which are incorporated herein as reference.
  • PCT publication WO 2010/004339 discloses a process for preparation of sunitinib L-malate by mixing sunitinib with suitable solvents like acetone, methanol or ethyl acetate followed by adding malic acid to yield crystal form I of sunitinib malate.
  • PCT publication WO 2010/01 1834 discloses a process for preparation of sunitinib L-malate by dissolving sunitinib in solvents like pyridine, dioxane, butyl acetate, ethyl acetate, N-methyl pyrrolidone or toluene, N-methyl pyrrolidone or propanol, dimethylacetamide or n-propanol followed by adding L-malic acid to form crystal form I of sunitinib malate.
  • solvents like pyridine, dioxane, butyl acetate, ethyl acetate, N-methyl pyrrolidone or toluene, N-methyl pyrrolidone or propanol, dimethylacetamide or n-propanol
  • This application also discloses another method for the preparation of sunitinib malate through acid addition salt of sunitinib wherein in acid is selected from acetic acid, formic acid, ascorbic acid, benzoic acid, succinic acid, n-butyric acid, propionic acid and boric acid.
  • PCT publication WO 2010/041 134 discloses a process for preparation of sunitinib malate by reacting 5-formyl-2,4-lH-pyrrole-3-carboxylic acid-(2-diethylaminoethyl) amide with 5-fluoro- l ,3- dihydro-indol-2-one in butanol in the presence of pyrrolidine followed by addition of acetic acid to reaction mixture to directly form sunitinib acetate without isolating sunitinib base.
  • Sunitinib acetate thus formed is then reacted with L-malic acid in n-butanol to form sunitinib malate which is crystallized using water: isopropanol.
  • PCT publication WO 2010/049449 exemplifies synthesis of sunitinib salts using different acids selected from D-tartaric acid, L-tartaric acid and citric acid. Patent is completely silent about the conversion of above sunitinib salts to sunitinib malate which is active ingredient for drug product.
  • PCT publication WO 2010/076805 discloses a process for preparation of sunitinib L-malate by refluxing sunitinib base, L-malic acid in a solvent like dimethylsulfoxide to obtain a clear solution followed by adding antisolvent or mixture of antisolvents selected from acetone, methyl tert-butyl ether and isopropyl acetate to give crystal form I of sunitinib malate.
  • present invention fulfills the need in of the art and provides a process for the preparation of sunitinib wherein use of expensive and hazardous reagent such as pyrrolidine or Vilsmeier reagent is avoided and proved to be simple, efficient and industrially advantageous.
  • Present invention also provides efficient and improved process for the synthesis of crystalline form I of sunitinib malate, wherein form I can be prepared in pure form without contamination of other forms, consistently.
  • the principal objective of present invention is to provide an industrially advantageous and cost effective process for the synthesis of sunitinib and pharmaceutically acceptable salts thereof.
  • Another object of the present invention is to provide an industrially advantageous process for the preparation of sunitinib which circumvent the use of expensive reagent such as pyrrolidine.
  • Another object of the present invention is to provide an industrially advantageous process for the preparation of sunitinib which circumvent the use of corrosive reagent such as Vilsmeier reagent.
  • Another object of the present invention is to provide novel acid addition salts of sunitinib.
  • Yet another object of present invention is to provide an efficient process for preparation of crystalline form I of sunitinib L-malate.
  • present invention provides an improved and industrially advantageous process for the preparation of sunitinib of formula I ,
  • present invention provides improved processes for preparation of sunitinib and its L-malate salt.
  • present invention provides an improved process for the preparation of sunitinib and pharmaceutically acceptable salts thereof, comprising the steps of:
  • step b) optionally, neutralizing the product obtained in step a) with a suitable base;
  • the present invention provides a process for the preparation of crystalline form I of sunitinib malate, comprising the steps of :
  • the present invention provides a process for preparation of form I of sunitinib malate, comprising the steps of;
  • step b) optionally, neutralizing the product obtained in step a) with a suitable base;
  • the present invention provides novel salt of sunitinib with protic acid selected from hydrochloric acid, hydrobromic acid, oxalic acid, lavulinic acid, salicylic acid, phosphoric acid, sulfuric acid, picric acid.
  • protic acid selected from hydrochloric acid, hydrobromic acid, oxalic acid, lavulinic acid, salicylic acid, phosphoric acid, sulfuric acid, picric acid.
  • the present invention provides a process for preparation of sunitinib with enhanced purity using novel salts.
  • the present invention provides sunitinib hydrochloride salt in isolated form, both in amorphous as well as crystalline.
  • present invention provides crystalline sunitinib hydrochloride.
  • present invention provides crystalline sunitinib hydrobromide.
  • the present invention provides sunitinib hydrobromide salt in isolated from, both in amorphous as well as crystalline.
  • the present invention provides sunitinib phosphate in isolated form, both in amorphous as well as crystalline.
  • the present invention provides sunitinib salicylate in isolated form, both in amorphous as well as crystalline.
  • Figure 1 shows X-ray powder diffraction pattern of sunitinib hydrochloride
  • Figure 2 shows X-ray powder diffraction pattern of sunitinib hydrobromide
  • the present invention provides a process for the preparation of sunitinib of formula I and pharmaceutically acceptable salts thereof by the condensation of indole intermediate of formula II with formyl amide intermediate of formula III using a suitable condensing reagent.
  • process involves reaction of indole intermediate of formula II with formyl amide intermediate of formula III in the presence of a suitable condensing reagent at a temperature of 10 to 150 °C for few minutes to several hours, preferably till completion of condensation reaction.
  • suitable condensing reagent can be selected from protic acid such as hydrochloric acid, hydrobromic acid, oxalic acid, lavulinic acid, salicylic acid, phosphoric acid, sulfuric acid, picric acid and the like; phenols, substituted phenol; acid salts such as sodium bisulfite; ammonium picrate and the like.
  • Protic acid employed for the reaction can be used as such or in mixture with a suitable solvent selected from alcohol such as methanol, ethanol, iso-propanol; ester such as ethyl acetate; ketone such as acetone, methyl isobutyl ketone, methyl ethyl ketone; ether such as isopropyl ether, methyl tert-butyl ether; halogenated solvent such as dichloromethane, chloroform and the like.
  • a suitable solvent selected from alcohol such as methanol, ethanol, iso-propanol; ester such as ethyl acetate; ketone such as acetone, methyl isobutyl ketone, methyl ethyl ketone; ether such as isopropyl ether, methyl tert-butyl ether; halogenated solvent such as dichloromethane, chloroform and the like.
  • Source of hydrochloric acid is not limited to aqueous hydrochloric acid, concentrated hydrochloric acid, solution of hydrogen chloride in suitable solvent selected from CMO alcohols like methanol, ethanol, isopropanol,; C4-i 2 ester like ethyl acetate, C3.12 ketones like acetone, C 4 .i 2 ethers like isopropyl ether; aliphatic halogenated hydrocarbon like dichloromethane and the like.
  • Solution of hydrogen chloride can be prepared by purging dry hydrogen chloride gas in a solvent.
  • other acid can be employed as aqueous, concentrated or in mixture with solvents or any other suitable source of acid can be used for the condensation reaction.
  • Reaction can be carried out in a suitable solvent which can be selected from CMO alcohol such as methanol, ethanol, isoproanol, n-butanol; C 3- i 2 ketone such as acetone, ethyl methyl ketone, methyl isobutyl ketone; halogenated solvent such as dichloromethane, chloroform; C 4- i 2 ether such as 1,2-dimethoxy ethane, 1 ,4-dioxane, diethyl ether, isopropyl ether, methyl tertiary butyl ether, tetrahydrofuran, 2-methyl tetrahydrofuran, cyclopentyl methyl ether, C 4- i 2 ester such as ethyl acetate and the like or mixture thereof.
  • CMO alcohol such as methanol, ethanol, isoproanol, n-butanol
  • C 3- i 2 ketone such as acetone
  • Quantity of the condensing reagent used for the reaction can vary up to 6 mol equivalent.
  • protic acid can be employed in catalytic amount or stoichiometric amount.
  • reaction can be carried out at ambient temperature to reflux temperature. It generally takes 2 hours for completion of reaction.
  • Reaction monitoring can be performed by suitable chromatography techniques such as high performance liquid chromatography (HPLC), ultra pressure liquid chromatography (UPLC), thin layer chromatography (TLC) or gas chromatography (GC) and the like.
  • HPLC high performance liquid chromatography
  • UPLC ultra pressure liquid chromatography
  • TLC thin layer chromatography
  • GC gas chromatography
  • Dilution can be performed by adding suitable solvent selected from alcoholic solvent such as methanol, ethanol, isopropanol, n-butanol and the like or mixture thereof or mixture with other solvents which includes halogenated solvents such as dichloromethane; ether such as tetrahydrofuran, methyl tertiary butyl ether; ketone; nitrile such as acetonitrile and the like.
  • suitable solvent selected from alcoholic solvent such as methanol, ethanol, isopropanol, n-butanol and the like or mixture thereof or mixture with other solvents which includes halogenated solvents such as dichloromethane; ether such as tetrahydrofuran, methyl tertiary butyl ether; ketone; nitrile such as acetonitrile and the like.
  • Resulting product can be isolated from the resulting mixture by using suitable techniques such as filtration, centrifugation and the like.
  • Product obtained from the reaction can be sunitinib free base or sunitinib salt depending upon the nature as well as on the quantity of condensing reagent used for the reaction.
  • reaction mass can be optionally washed with a suitable base to remove extra acid, if present, to give sunitinib free base.
  • reaction can be carried out using stoichiometric to 6 mol equivalent of protic acid which yields corresponding sunitinib salts, which form other novel part of the invention.
  • Present invention provides novel salts of sunitinib with a protic acid selected from hydrochloric acid, hydrobromic acid, oxalic acid, lavulinic acid, salicylic acid, phosphoric acid, sulfuric acid, picric acid and the like, preferably sunitinib hydrochloride, sunitinib hydrobromide.
  • a protic acid selected from hydrochloric acid, hydrobromic acid, oxalic acid, lavulinic acid, salicylic acid, phosphoric acid, sulfuric acid, picric acid and the like, preferably sunitinib hydrochloride, sunitinib hydrobromide.
  • Novel salts of sunitinib as described by the present invention can be amorphous or crystalline.
  • Sunitinib salt can be characterized by suitable spectroscopic techniques such as Infra-red spectroscopy (IR), nuclear magnetic spectroscopic ( ⁇ -NMR and/or l 3 C-N R), mass analysis, melting point and the like. Polymorphic nature of the sunitinib salt can be checked by the differential scanning calorimetric (DSC) and/or powder X-ray diffraction pattern (PXRD) and the like.
  • IR Infra-red spectroscopy
  • ⁇ -NMR nuclear magnetic spectroscopic
  • l 3 C-N R nuclear magnetic spectroscopic
  • mass analysis melting point and the like.
  • Polymorphic nature of the sunitinib salt can be checked by the differential scanning calorimetric (DSC) and/or powder X-ray diffraction pattern (PXRD) and the like.
  • DSC differential scanning calorimetric
  • PXRD powder X-ray diffraction pattern
  • Sunitinib hydrochloride shows the powder X-ray diffraction pattern as shown in Figure 1 .
  • Sunitinib hydrochloride having a melting point falling in a range of 275 to 285 °C.
  • Sunitinib hydrobromide is also analyzed by powder X-ray diffraction technique which displays X-ray diffraction pattern as shown in Figure 2.
  • Sunitinib hydrobromide having a melting point falling in a range of 288 to 298 °C.
  • polymorphic nature and other characteristic of sunitinib salts can be characterized by any suitable technique in known in the art.
  • Sunitinib salts can be direct product of condensation reaction or can be alternatively prepared by the reaction of sunitinib free base with a suitable acid.
  • present invention provides a process for the preparation of sunitinib salt by reaction of sunitinib free base with a suitable acid.
  • sunitinib free base is treated with a suitable acid at a temperature of 10 °C to boiling point of the solvent system for a time period sufficient for the salt formation.
  • Suitable acid can be selected from but not limited to hydrochloric acid, hydrobromic acid, oxalic acid, lavulinic acid, salicylic acid, phosphoric acid, sulfuric acid, picric acid and the like.
  • Acid employed for the salt formation can be used as such or in mixture with a suitable solvent selected from alcohol, ester, ketone, ether, halogenated solvent, and the like.
  • Source of hydrochloric acid is not limited to aqueous hydrochloric acid, concentrated hydrochloric acid, solution of hydrogen chloride in suitable solvent selected from Ci-io alcohols like methanol, ethanol, isopropanol,; C 4- i 2 ester like ethyl acetate, C 3- i 2 ketones like acetone, C 4- i 2 ethers like isopropyl ether; aliphatic halogenated hydrocarbon like dichloromethane and the like.
  • Solution of hydrogen chloride can be prepared by purging dry hydrogen chloride gas in a solvent.
  • other acid can be employed as aqueous, concentrated or in mixture with solvents or any other suitable source of acid can be used for the salt formation.
  • Salt formation can be carried out in the presence of a suitable solvent which includes water, alcohols, ketones, ethers, aliphatic or aromatic hydrocarbon, solvent, halogenated solvent, nitriles, esters and the like or mixture thereof.
  • Sunitinib salt thus prepared can be isolated from the reaction mixture or can be in situ neutralized to form sunitinib free base.
  • sunitinib salt can be isolated from the reaction mixture by suitable techniques such as filtration, centrifugation, decantation and the like.
  • Sunitinib salt thus prepared by the process of present invention can be in isolated form or can be used in situ without isolation for the neutralization reaction with a suitable base to provide pure sunitinib.
  • process involves neutralization of sunitinib salt with a suitable base at a temperature of 0 to 30 °C for 0.5 hours to several hours, preferably at a temperature of 10 to 25 °C to 1 to 3 hours, more preferably till completion of the neutralization.
  • Suitable base used for the neutralization can be organic or inorganic base.
  • Sunitinib salts to be neutralized can be acid salt of sunitinib with acid selected from but not limited to protic acid selected from hydrochloric acid, hydrobromic acid, oxalic acid, lavulinic acid, salicylic acid, phosphoric acid, sulfuric acid, picric acid and the like.
  • Suitable base employed for the neutralization reaction can be selected from any base known in the art that can serve the purpose of neutralization and can be selected depending upon nature and amount of acid to be neutralized.
  • suitable base includes but not limited to organic bases such as ammonia, triethylamine, diisopropylethylamine and the like; or inorganic base can be selected from alkali or alkaline metal hydroxides, carbonates, bicarbonate, alkoxide thereof such as lithium, sodium and potassium hydroxide, carbonates, bicarbonate, alkoxide and the like.
  • sunitinib can be isolated from the reaction mixture or can be reacted in situ with malic acid to form sunitinib malate.
  • sunitinib can be isolated from the reaction mixture by suitable techniques such as filtration, centrifugation and the like.
  • Sunitinib thus prepared can be optionally purified to enhance the purity and/or to minimize the impurities present in it.
  • Any suitable purification method can be employed for purification of sunitinib, preferably sunitinib can be crystallized or slurry washed in a suitable solvent.
  • sunitinib can be stirred in a suitable solvent at a temperature of 0 to 150 °C for 1 to 48 hours.
  • reaction mixture can be stirred at a temperature of 25 to 80 °C for 12 hours.
  • Suitable solvent includes CMO alcohol such as methanol, ethanol, n-butanol, isopropanol and the like or mixture thereof or mixture with other solvent selected from C 4-]2 ether such as tetrahydrofuran, 2- methyl tetrahydrofuran, methyl tertiary butyl ether; halogenated solvents such as dichloromethane; ketone such as methyl isobutyl ketone; nitrile such as acetonitrile and the like. Thereafter, purified product can be recovered from the resulting mixture using suitable techniques such as filtration, centrifugation and the like.
  • CMO alcohol such as methanol, ethanol, n-butanol, isopropanol and the like or mixture thereof or mixture with other solvent selected from C 4-]2 ether such as tetrahydrofuran, 2- methyl tetrahydrofuran, methyl tertiary butyl ether
  • halogenated solvents such as dich
  • Sunitinib thus prepared can be converted to sunitinib malate by any method known in the art.
  • sunitinib is converted to sunitinib malate crystalline form I.
  • Sunitinib can be converted to crystalline form I of sunitinib malate using methyl isobutyl ketone or a mixture of methyl isobutyl ketone with other solvents which forms another novel feature of the invention.
  • the process involves reaction of sunitinib in a solvent with malic acid at a temperature of 0 to 150 °C for 1 to 48 hours.
  • salt formation can be carried out at a temperature from 15 °C to 100 °C for 1 to 24 hours, more preferably at a temperature of 20 to 75 °C for 1 to 6 hours.
  • Suitable solvent used for the salt formation can be selected from methyl isobutyl ketone or a mixture of methyl isobutyl ketone with other solvents which are not limited to methanol, methyl tertiary butyl ether, 2-methyl tetrahydrofuran, ethyl acetate and the like or mixture thereof.
  • Malic acid used for the reaction is preferably L-malic acid. Sufficient amount of malic acid can be added to the reaction mixture so that whole of the sunitinib reacts with malic acid. After completion of salt formation, sunitinib malate crystalline form I can be isolated using suitable techniques such as filtration, centrifugation and the like.
  • Starting materials of formulae 11 and III used in present invention can be prepared by prior art method or can be procured from commercial sources.
  • formyl amide intermediate of formula III can be prepared by the method as described herein for reference.
  • Formyl amide intermediate of formula III can be prepared by the amidation of 5-formyl-2,4- dimethyl-1 H-pyrrole-3-carboxylic acid of formula,
  • process involves amidation of 5-formyl-2,4-dimethyl-l H-pyrrole-3-carboxylic acid with N,N- diethylaminoethylamine in the presence of coupling agent at a temperature of -20 to 120 °C for 1 to 24 hours, preferably till completion of reaction.
  • Coupling agent used for the reaction can be l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride with or without additives such as hydroxybenzotriazole and the like.
  • process involves addition of a suitable base in addition to coupling agent.
  • Suitable base can be selected from organic base such as tertiary amine such as triethylamine, diisopropyl ethyl amine and the like; or inorganic base can be selected from alkali or alkaline metal hydroxide, carbonates, bicarbonates, silyl amide or hydride thereof such as lithium carbonate, sodium carbonate, potassium carbonate, lithium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydride, lithium hydride, potassium bis(trimethyl)silylamide, sodium bis(trimethyl)silylamide, lithium bis(trimethyl)silylamide, lithium bicarbonate and the like.
  • organic base such as tertiary amine such as triethylamine, diisopropyl ethyl amine and the like
  • inorganic base can be selected from alkali or alkaline metal hydroxide, carbonates, bicarbonates, silyl amide or hydride thereof such as lithium carbonate, sodium carbonate, potassium carbonate, lithium
  • Solvent employed for the reaction is not critical and can be selected from ether such as tetrahydrofuran, 2- methyl tertrahydrofuran, methyl tert-butyl ether, isopropyl ether, dioxane, 1 ,2-dimethoxyethane and the like or mixture thereof.
  • reaction mixture is stirred for 2 to 18 hours at temperature of 0 to 100 °C.
  • Reaction completion can be monitored by HPLC, TLC, UPLC or GC.
  • a suitable base is added to the reaction mixture followed by extraction with water immiscible solvent, in which desired product has more solubility.
  • Suitable base can be selected from alkali metal carbonate or bicarbonate thereof such as sodium bicarbonate, sodium carbonate and the like.
  • Water immiscible solvent used for extraction can be selected from halogenated solvent such as dichloromethane; alcohols such as methanol, ethanol, iso-propanol, n-butanol or mixture thereof in any suitable proportions.
  • Resulting organic solvent can be optionally washed with water followed by solvent removal by any suitable technique known in the art such as distillation, evaporation and the like, to give desired product.
  • Resulting compound can be optionally purified to enhance purity and/or to remove impurity in the product.
  • Any suitable purification method can be employed such as slurry wash, crystallization, base acid treatment and the like.
  • formyl intermediate of formula III can be stirred with a suitable solvent at a temperature of - 10 to 120 °C for 10 minutes to 8 hours.
  • Solvent can be selected from ether such as methyl tert-butyl ether, isopropyl ether; aliphatic hydrocarbon such as cyclohexane, n-heptane and the like.
  • Product can be isolated from the mixture by removal of solvent using suitable techniques such as filtration, centrifugation and the like.
  • formyl intermediate of formula III can be purified by treatment with a base followed by extraction using water immiscible solvent.
  • process involves treatment of formyl intermediate of formula III in a solvent with a suitable base at a temperature of -10 to 120 °C followed by addition of water immiscible solvent.
  • Reaction mixture is stirred for 10 minutes to 8 hours.
  • reaction mixture is stirred for 1 to 3 hour.
  • Solvent used can be selected from water and the like.
  • Suitable base employed can be selected from alkali or alkaline metal carbonate or bicarbonate such as sodium bicarbonate, potassium bicarbonate and the like.
  • Water immiscible solvent selected from halogenated solvent such as dichloromethane; alcohol such as methanol, ethanol, iso-propanol, n-butanol or mixture thereof in any suitable proportion.
  • Purified product can be isolated from the mixture by solvent removal using suitable techniques such as distillation, evaporation and the like.
  • 5-formyl-2,4-dimethyl-l H-pyrrole-3-carboxylic acid can be prepared by any method known in art hydrolysis of corresponding ester intermediate of formula, herein R is selected from alk l group such as methyl, ethyl and the like
  • process involves treatment of ester intermediate in a solvent with a suitable base at a temperature of 0 to 120 °C for few minutes to several hours, preferably till completion of hydrolysis.
  • Suitable base employed for the reaction include alkali metal hydroxide, carbonates, bicarbonate such as potassium hydroxide, sodium hydroxide and the like.
  • Solvent used can be selected from water, alcohol such as methanol, ethanol, ethanol, iso-propanol, n-butanol and the like or mixture thereof.
  • reaction mixture can be optionally cooled to 5 °C to ambient temperature followed by washing with water immiscible solvent selected from ester such as ethyl acetate; ether such as isopropyl ether, methyl tert-butyl ether; aromatic hydrocarbon such as toluene; halogenated solvent such as dichloromethane and the like.
  • water immiscible solvent selected from ester such as ethyl acetate; ether such as isopropyl ether, methyl tert-butyl ether; aromatic hydrocarbon such as toluene; halogenated solvent such as dichloromethane and the like.
  • 5-Formyl-2,4-dimethyl-lH-pyrrole-3- carboxylic acid can be isolated from resulting aqueous layer by acidification using suitable acid.
  • Acid can be selected from hydrochloric acid, phosphoric acid, sulfuric acid, hydrobromic acid, carboxylic acid, alkane sulfonic acid and
  • Acid intermediate thus prepared, can be optionally purified using base-acid treatment to enhance purity of product and/or to remove impurities.
  • process involves treatment of acid intermediate with a suitable base at a temperature of 0 to 120 °C for 30 minutes to 10 hours, preferably till clear solution is obtained.
  • Solvent employed for the reaction is not critical and can be selected from water; alcohol such as methanol and the like.
  • Suitable base can be selected from alkali or alkaline metal hydroxide such as potassium hydroxide, sodium hydroxide and the like.
  • Reaction mixture is charcoalized and then acidified to precipitate acid intermediate. Purified product can be isolated from the mixture using suitable techniques such as filtration, centrifugation and the like.
  • Major advantage realized in the present invention is that it avoids the use of expensive and toxic reagents during preparation of sunitinib and employs use of acidic reagents which proved to be highly effective as well as economically suitable for the industrial synthesis of sunitinib.
  • Present invention also provides novel salts of sunitinib which are highly advantageous in yielding pure sunitinib free base. Further present invention provides an efficient process for preparation of pure sunitinib malate form I consistently.
  • Resulting product was extracted with a mixture of dichloromethane- methanol (5% methanol, 3 x 10 L). The organic layers were combined, washed with demineralized water (2 x 5L). Solvent was distilled off from resulting organic layer. Methyl tert-butyl ether (5 L) was added to resulting product and stirred at 45-50 °C for 30 minutes. Mixture was cooled to ambient temperature and resulting product was filtered. Filtered solid was washed with methyl tert- butyl ether (5L) and dried.
  • Method A A mixture of 5-fluoro-l,3-dihydro-indol-2-one (1 g), 5-formyl-2,4-dimethyl-lH- pyrrole-3-carboxylic acid-(2-diethylaminoethyl) amide (1.8 g), methanol (20 ml) and methanolic hydrochloride (10 %, 0.3 ml) was refluxed for 2 hours, followed by cooling to room temperature. The reaction mixture was diluted with methanol (20 ml). Reaction mixture was filtered and washed with methanol (10 ml). Resulting product was neutralized with aqueous ammonia (25 %, 3 ml) and stirred for 30 minutes. The product thus obtained was filtered, washed with water (10 ml) and dried to give the 2.1 g of the title compound having purity 99 % by HPLC.
  • Method B A mixture of 5-fluoro-l ,3-dihydro-indol-2-one (1 g), 5-formyl-2,4-dimethyl-lH-pyrrole- 3-carboxylic acid-(2-diethylaminoethyl) amide (1.8 g), methanol (20 ml) and aqueous hydrobromide (47 %, 0.1 ml) was refluxed for 2 hours, followed by cooling to room temperature. The reaction mixture was diluted with methanol (20 ml). Reaction mixture was filtered and washed with methanol (10 ml). Resulting product was neutralized with aqueous ammonia (25 %, 3 ml) and stirred for 30 minutes. The product thus obtained was filtered, washed with water (10 ml) and dried to give the 2.0 g of th'e title compound having purity 97.6 % by HPLC.
  • Method A Sunitinib (1.3 g) was taken in methyl isobutylketone (39 ml) and L- alic acid (0.472 g) was added to the above mixture. Reaction mixture was stirred for 3 hours at room temperature. The product thus obtained was filtered and dried to give 1.3 g of title compound having purity 99.6 % by HPLC.
  • Method B Sunitinib (1 g) was added to a stirred mixture of methyl isobutylketone (10 ml) and methyl tertiary butyl ether (10 ml) followed by addition of L-malic acid (0.360 g). Reaction mixture was stirred for 2 hours at room temperature. The product thus obtained was filtered and dried to give 1.2 g of title compound.
  • Method C Sunitinib (1 g) was added to a mixture of methyl isobutylketone (10 ml) and ethyl acetate (10 ml) followed by addition of L-malic acid (0.360 g). Reaction mixture was stirred for 2 hours at room temperature. The product thus obtained was filtered and dried to give 1.1 g of title compound.
  • Method D To a mixture of sunitinib (1 kg) in methyl isobutylketone (15 L), L-Malic acid (359 g) was added and heated to 50-55 °C for 2 hours. Resulting product was filtered and washed with ethanol (2 x 5 L). Solid, thus obtained, was dried in vacuum at 75-80 °C (150mmHg) to give 1.27 kg of title compound.

Abstract

L'invention concerne un procédé pour la préparation de malate de sunitinib, lequel procédé consiste à condenser un intermédiaire indole avec un intermédiaire formylamide. L'inveniton concerne également un procédé pour la préparation de la forme cristalline I du malate de sunitinib, lequel procédé consiste à utiliser du méthyl-isobutyl-cétone en tant que solvant.
PCT/IN2011/000748 2010-11-04 2011-10-28 Procédé pour préparation de malate de sunitinib et sels correspondants WO2012059941A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2652/DEL/2010 2010-11-04
IN2652DE2010 2010-11-04

Publications (1)

Publication Number Publication Date
WO2012059941A1 true WO2012059941A1 (fr) 2012-05-10

Family

ID=46024088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000748 WO2012059941A1 (fr) 2010-11-04 2011-10-28 Procédé pour préparation de malate de sunitinib et sels correspondants

Country Status (1)

Country Link
WO (1) WO2012059941A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103274986A (zh) * 2013-06-20 2013-09-04 湖南欧亚生物有限公司 一种舒尼替尼中间体的合成和精制方法
CN103319392A (zh) * 2013-07-10 2013-09-25 张家港市华昌药业有限公司 一种舒尼替尼中间体的制备方法
WO2013140232A1 (fr) 2012-03-23 2013-09-26 Laurus Labs Private Limited Procédé perfectionné pour la préparation de sunitinib et de ses sels d'addition avec un acide
WO2013162390A1 (fr) * 2012-04-27 2013-10-31 Instytut Farmaceutyczny Procédé de préparation de n-[2-(diéthylamine)éthyl]-5-formyl-2,4-diméthyl-1h-pyrrole-3-carboxyamide de pureté élevée
WO2015056247A1 (fr) * 2013-10-18 2015-04-23 Ranbaxy Laboratories Limited Forme cristalline ii pure de sel d'acide l-malique du sunitinib et procédés pour sa préparation
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN105085490A (zh) * 2014-05-09 2015-11-25 上海科胜药物研发有限公司 新的舒尼替尼苹果酸盐晶型及其制备方法
WO2021125788A1 (fr) * 2019-12-17 2021-06-24 주식회사 삼양홀딩스 Préparation solide pour administration orale contenant du chlorhydrate de sunitinib et son procédé de préparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1439005A (zh) * 2000-02-15 2003-08-27 苏根公司 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂
CN101497607A (zh) * 2008-01-29 2009-08-05 上海百灵医药科技有限公司 舒尼替尼的合成方法
WO2010049449A2 (fr) * 2008-10-28 2010-05-06 Lek Pharmaceuticals D.D. Nouveaux sels de sunitinib
WO2010055082A2 (fr) * 2008-11-13 2010-05-20 Lek Pharmaceuticals D.D. Nouvelle forme cristalline de malate de sunitinib

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1439005A (zh) * 2000-02-15 2003-08-27 苏根公司 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂
CN101497607A (zh) * 2008-01-29 2009-08-05 上海百灵医药科技有限公司 舒尼替尼的合成方法
WO2010049449A2 (fr) * 2008-10-28 2010-05-06 Lek Pharmaceuticals D.D. Nouveaux sels de sunitinib
WO2010055082A2 (fr) * 2008-11-13 2010-05-20 Lek Pharmaceuticals D.D. Nouvelle forme cristalline de malate de sunitinib

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013140232A1 (fr) 2012-03-23 2013-09-26 Laurus Labs Private Limited Procédé perfectionné pour la préparation de sunitinib et de ses sels d'addition avec un acide
WO2013162390A1 (fr) * 2012-04-27 2013-10-31 Instytut Farmaceutyczny Procédé de préparation de n-[2-(diéthylamine)éthyl]-5-formyl-2,4-diméthyl-1h-pyrrole-3-carboxyamide de pureté élevée
CN103274986A (zh) * 2013-06-20 2013-09-04 湖南欧亚生物有限公司 一种舒尼替尼中间体的合成和精制方法
CN103319392A (zh) * 2013-07-10 2013-09-25 张家港市华昌药业有限公司 一种舒尼替尼中间体的制备方法
CN103319392B (zh) * 2013-07-10 2015-10-28 张家港市华昌药业有限公司 一种舒尼替尼中间体的制备方法
WO2015056247A1 (fr) * 2013-10-18 2015-04-23 Ranbaxy Laboratories Limited Forme cristalline ii pure de sel d'acide l-malique du sunitinib et procédés pour sa préparation
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN105085490A (zh) * 2014-05-09 2015-11-25 上海科胜药物研发有限公司 新的舒尼替尼苹果酸盐晶型及其制备方法
WO2021125788A1 (fr) * 2019-12-17 2021-06-24 주식회사 삼양홀딩스 Préparation solide pour administration orale contenant du chlorhydrate de sunitinib et son procédé de préparation
KR20210077626A (ko) * 2019-12-17 2021-06-25 주식회사 삼양홀딩스 수니티닙 염산염을 포함하는 경구용 고형제제 및 그 제조 방법
KR102538075B1 (ko) * 2019-12-17 2023-05-30 주식회사 삼양홀딩스 수니티닙 염산염을 포함하는 경구용 고형제제 및 그 제조 방법

Similar Documents

Publication Publication Date Title
WO2012059941A1 (fr) Procédé pour préparation de malate de sunitinib et sels correspondants
US8501962B2 (en) Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
EP2025672B1 (fr) Procédé de production de composés 1-carbamoyl-3,7-dioxo-1,4-diazépane
US8501960B2 (en) Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
US20110105580A1 (en) Novel polymorphic forms of sunitinib base
US20160176818A1 (en) Method For Preparing Silodosin
WO2009083739A1 (fr) Procédé de synthèse du bosentan, de ses formes polymorphiques et de ses sels
JP7136527B2 (ja) ３－［（３ｓ）－７－ブロモ－２－オキソ－５－（ピリジン－２－イル）－２，３－ジヒドロ－１ｈ－［１，４］－ベンゾジアゼピン－３－イル］プロピオン酸メチルエステルの調製方法及びその方法に有用な化合物
KR101202209B1 (ko) 무스카린 수용체 길항 작용약의 제조방법 및 이의 중간체
US20060199855A1 (en) Process for producing atorvastatin hemicalcium
WO2012004811A1 (fr) Procédé pour la préparation de dérivé d'indole substitué en position 5
CN111051289A (zh) 被保护的l-肌肽衍生物、l-肌肽以及结晶性l-肌肽锌络合物的制造方法
US7943784B2 (en) Process for the preparation of almotriptan
JP2015038053A (ja) ４−（２−メチル−１−イミダゾリル）−２，２−フェニルブタンアミドの製造方法
US8093384B2 (en) Processes for the preparation of alfuzosin
US20100174073A1 (en) Process for the preparation of alfuzosin and salts thereof
US20190314385A1 (en) Process for Preparation of Chlorpromazine or its Pharmaceutically Acceptable Salts
EP2264027A1 (fr) Processus pour la préparation de N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2013162390A1 (fr) Procédé de préparation de n-[2-(diéthylamine)éthyl]-5-formyl-2,4-diméthyl-1h-pyrrole-3-carboxyamide de pureté élevée
HRP20000683A2 (en) Process for the production of r-(+)-6-carboxamido-3-n-methylamino-1,2,3,4-tetrahydrocarbazole
US7265238B2 (en) Process for preparing methyl 4-(aminomethyl)benzoate
BR112012029363B1 (pt) Processo para preparar 1-alquil-3-difluorometil-5 -hidroxipirazóis
WO2006021968A1 (fr) PROCESSUS DE PRÉPARATION DE 4-FLUORO-α-[2-MÉTHYL-1-OXOPROPYL]Ϝ-OXO-N-β-AMIDE DE BUTANE DE DIPHÉNYLBENZÈNE
EP3759081A1 (fr) Procédé de préparation amélioré de maléate de propiomazine
CN110885315A (zh) 左西孟旦药重要中间体的制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11837678

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11837678

Country of ref document: EP

Kind code of ref document: A1